The research progress of PROTACs for breast cancer treatment
10.16438/j.0513-4870.2020-0340
- VernacularTitle:针对乳腺癌治疗的PROTACs研究进展
- Author:
Bao-hua XIE
1
;
Zhi-ye HU
1
;
Wen-tao NING
1
;
Lu YANG
2
,
3
;
Hai-bing ZHOU
1
,
3
Author Information
1. Hubei Province Engineering and Technology Research Centre for Fluorinated Pharmaceuticals, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
2. Radiological Molecular Imaging Laboratory, Department of Radiology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
3. The State Key Laboratory of Virology, Wuhan 430072, China
- Publication Type:Research Article
- Keywords:
breast cancer;
target;
rug resistance;
PROTACs
- From:
Acta Pharmaceutica Sinica
2020;55(9):2053-2061
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor in women worldwide. In breast cancer tumor tissues, a variety of targets related to the occurrence and development of breast cancer have been observed, and many drugs have been used in clinical applications for these targets. However, most of these drugs are small molecule inhibitors. With the long-term use of these drugs, acquired drug resistance often occurs in breast cancer patients. To overcome the drug resistance, the development of more efficient drugs is highly desirable in the treatment of breast cancer. Proteolysis targeting chimera (PROTAC) technology is a new kind of targeted protein degradation technology, which has shown broad prospect of applications in the field of drug development. The use of PROTAC technology to target the degradation of relevant targets in breast cancer has become a feasible strategy for breast cancer treatment.
